CROSS side effects

Although the antibacterial spectmm is similar for many of the sulfas, chemical modifications of the parent molecule have produced compounds with a variety of absorption, metaboHsm, tissue distribution, and excretion characteristics. Administration is typically oral or by injection. When absorbed, they tend to distribute widely in the body, be metabolized by the Hver, and excreted in the urine. Toxic reactions or untoward side effects have been characterized as blood dyscrasias crystal deposition in the kidneys, especially with insufficient urinary output and allergic sensitization. Selection of organisms resistant to the sulfonamides has been observed, but has not been correlated with cross-resistance to other antibiotic families (see Antibacterial AGENTS, synthetic-sulfonamides). 

The cephalosporins generally cause few side effects (80,132,219—221). Thrombophlebitis occurs as a result of intravenous administration of all cephalosporins. Hypersensitivity reactions related to the cephalosporins are the most common side effects observed, but these are less common than found with the penicillins. Clinically only about 5—10% of patients with allergic reactions to the penicillins manifest the same reactions to the cephalosporins, and data would contradict any tme cross-reactivity to cephalosporins in patients who have previously reacted to penicillin (80,132,219). 

Cross-linked finishes are not permanent in the tme sense of the word however, under optimum conditions the finish can last for the usehil life of the material. Wet abrasion during laundering is probably the principal cause of gradual removal of the finish. In order to retain antistatic protection for extended use, an excess of finish is often appHed The extent of chemical interaction between the durable antistatic agents and the fiber substrates to which they are appHed is not perfectiy understood. Certain oxidizing agents such as hypochlorite bleaches tend to depolymerize and remove some durable antistatic finishes. Some of the durable finishes have also produced undesirable side effects on textile materials, ie, harsh hand, discoloration, and loss of tensile properties. 

Toxic effects of propranolol are related to its blocking P-adrenoceptor blocking actions. They include cardiac failure, hypotension, hypoglycemia, and bronchospasm. Propranolol is lipophilic and crosses the blood—brain barrier. Complaints of fatigue, lethargy, mental depression, nightmares, hallucinations, and insomnia have been reported. GI side effects include nausea, vomiting, diarrhea, and constipation (1,2). 

In those application where the cross-coupling effects from the oil seal were detrimental to the rotor dynamics, the use of the gas seal is a dis tinct advantage. However, the down side is that should the oil seal ha c provided a good measure of damping, the impact on the rotor dynamics is reversed. None of this is irreversible, but certainly must be kept m mind at the time of design. 

Column temperature alarm Not a complete indication at this stage. It may be a spurious alarm Cross-examine related indicators Data collection Can operator acquire irrelevant or insufficient data Can operator fail to crosscheck for spurious indications Identification/lnterpretation Can operator fail to consider all possible system states and causes of problem Can operator fail to perform a correct evaluation Can operator fixate on the wrong cause Goal Selection Can operator fail to consider possible side-effects Can operator fail to consider alternative goals Can operator fixate on the wrong goal ... 

The sedation side effect commonly observed on administration of classical antihistaminic drugs has been attributed in part to the ease with which many of these compounds cross the blood brain barrier. There have been developed recently a series of agoits, for example, terfenadine (198), which cause reduced sedation by virtue of decreased penetration into the CNS. This is achieved by making them more hydrophilic. Synthesis of a related compound, ebastine (197),... 

Temozolomide crosses the blood brain barrier and can be used for the treatment of brain tumors (e.g., glioblastoma multiforme). The most common side effects are nausea and vomiting. 

Dantrolene is the mainstay of MH treatment. It has long been available for the treatment of muscle spasm in cerebral palsy and similar diseases. It is a hydantoin derivative that was first synthesized in 1967, and reported to be effective in the treatment of porcine MH in 1975. Also in 1975, dantrolene was shown to be more effective than procainamide in the treatment of human MH, which until that time was the drug of choice. However, the intravenous preparation was not made available until November 1979. It significantly lowered mortality. The half-life of dantrolene is estimated to be 6-8 hr. Dantrolene s primary mode of action is the reduction in calcium release by the sarcoplasmic reticulum. Dantrolene also exerts a primary antiarrhythmic effect by increasing atrial and ventricular refractory periods. Side effects of dentrolene include hepatotoxicity, muscle weakness, ataxia, blurred vision, slurred speech, nausea, and vomiting. Dantrolene is not contraindicated in pregnancy, but it does cross into breast milk and its effect on the neonate is unknown. 

Xylan-based microparticles were also evaluated regarding their in vitro toxicity. In fact, cross-liked (CLM) and spray-dried microparticles (SDM) based on xylan and ESIOO were produced in order to carry UA and avoid its side effects, namely hepatotoxicity and nephrotoxicity. Additionally, CLM and SDM dispersions at concentrations of 50, 125, 250, and 500 pg/ml were placed in contact with human embiyonic Ixmg fibroblasts (MRC-5 cells)... 

The relaxation data for the anomeric protons of the polysaccharides (see Table II) lack utility, inasmuch as the / ,(ns) values are identical within experimental error. Obviously, the distribution of correlation times associated with backbone and side-chain motions, complex patterns of intramolecular interaction, and significant cross-relaxation and cross-correlation effects dramatically lessen the diagnostic potential of these relaxation rates. 

Carbidopa, a dopa-decarboxylase inhibitor, is added to the levodopa in order to decrease the peripheral conversion of levodopa to dopamine. It does not cross the blood-brain barrier and does not interfere with levodopa conversion in the brain. Concomitant administration of carbidopa and levodopa allows for lower levodopa doses and minimizes levodopa peripheral side effects such as nausea, vomiting, anorexia, and hypotension. For most patients, at least 75 to 100 mg daily of carbidopa is required to adequately block dopamine decarboxylase in the peripheral metabolism of levodopa in most patients. Taking extra carbidopa may reduce nausea related to initiating levodopa.8,16... 

Mitomycin C is an alkylating agent that forms cross-links with DNA to inhibit DNA and RNA synthesis. The pharmacokinetics of mitomycin C are best described by a two-compartment model, with an a half-life of 8 minutes and a terminal half-life of 48 minutes.31 Liver metabolism is the primary route of elimination. Mitomycin C has shown clinical activity in the treatment of anal, bladder, cervix, gallbladder, esophageal, and stomach cancer. Side effects consist of myelosuppression and mucositis, and it is a vesicant. 

Concerns about psychotropic side effects, which can vary cross-culturally, often lead to premature cessation of psychotropics. This may be related to different propensities for and values placed on somatic experiences in different cultures. Transcultural research indicates that patients from non-Western cultures are more likely to present with predominantly somatic symptoms of psychiatric disorders (Ng, 1997 Parker, Gladstone 8c Chee, 2001), as cultural explanatory models and social demands may serve to bias information processing in the various domains of subjective experience (Angel 8c Thoits, 1987). Several studies have shown that the perception and reporting of side effects are influenced by cultural beliefs... 

In fact, several pharmaceutical companies, such as Adolor, are developing per-ipheralized // and k analgesics which have been found to relieve pain but because they do not cross the blood-brain barrier do not cause the side effects of clinically... 

---